The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers
- PMID: 11448094
- DOI: 10.1177/026988110101500211
The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers
Abstract
Latent inhibition (LI) is a measure of reduced learning about a stimulus to which there has been prior exposure without any consequence. It therefore requires a comparison between a pre-exposed (PE) and a non-pre-exposed (NPE) condition. Since, in animals, LI is disrupted by amphetamines and enhanced by antipsychotics, LI disruption has been proposed as a measure of the characteristic attentional deficit in schizophrenia: the inability to ignore irrelevant stimuli. The findings in humans are, however, inconsistent. In particular, a recent investigation suggested that since haloperidol disrupted LI in healthy volunteers, and LI was normal in non-medicated patients with schizophrenia, the previous findings in schizophrenic patients were entirely due to the negative effects of their medication on LI (Williams et al., 1998). We conducted two studies of antipsychotic drug effects on auditory LI using a within-subject, parallel group design in healthy volunteers. In the first of these, single doses of haloperidol (1 mg. i.v.) were compared with paroxetine (20 mg p.o.) and placebo, and in the second, chlorpromazine (100 mg p.o.) was compared with lorazepam (2 mg. p.o.) and placebo. Eye movements, neuropsychological test performance (spatial working memory (SWM), Tower of London and intra/extra dimensional shift, from the CANTAB test battery) and visual analogue rating scales, were also included as other measures of attention and frontal lobe function. Haloperidol was associated with a non-significant reduction in LI scores, and dysphoria/akathisia (Barnes Akathisia Rating Scale) in three-quarters of the subjects. The LI finding may be explained by increased distractibility which was indicated by an increase in antisaccade directional errors in this group. In contrast, LI was significantly increased by chlorpromazine but not by an equally sedative dose of lorazepam (both drugs causing marked decreases in peak saccadic velocity). Paroxetine had no effect on LI, eye movements or CANTAB neuropsychological test performance. Haloperidol was associated with impaired SWM, which correlated with the degree of dysphoria/akathisia, but no other drug effects on CANTAB measures were detected. We conclude that the effect of antipsychotics on LI is both modality and pharmacologically dependent and that further research using a wider range of antipsychotic compounds is necessary to clarify the cognitive effects of these drugs, and to determine whether there are important differences between them.
Similar articles
-
Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers.J Psychopharmacol. 2004 Jun;18(2):156-72. doi: 10.1177/0269881104042614. J Psychopharmacol. 2004. PMID: 15260903
-
The effects of chlorpromazine and lorazepam on abnormal antisaccade and no-saccade distractibility.Biol Psychiatry. 1998 Oct 15;44(8):709-15. doi: 10.1016/s0006-3223(97)00452-6. Biol Psychiatry. 1998. PMID: 9798074 Clinical Trial.
-
Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration.J Clin Psychopharmacol. 2007 Feb;27(1):15-21. doi: 10.1097/jcp.0b013e31802dfff0. J Clin Psychopharmacol. 2007. PMID: 17224707 Clinical Trial.
-
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Clin Ther. 2008. PMID: 18840365 Review.
-
Psychomotor impairment and cognitive disturbances induced by neuroleptics.Acta Psychiatr Scand Suppl. 1994;380:53-8. doi: 10.1111/j.1600-0447.1994.tb05833.x. Acta Psychiatr Scand Suppl. 1994. PMID: 7914050 Review.
Cited by
-
Latent Inhibition in Schizophrenia and Schizotypy.Schizophr Bull Open. 2023 Nov 17;4(1):sgad026. doi: 10.1093/schizbullopen/sgad026. eCollection 2023 Jan. Schizophr Bull Open. 2023. PMID: 39145328 Free PMC article. Review.
-
A road less travelled by. A review lecture given to the Royal Irish Academy on the occasion of the Award of Merit and Silver Medal by the Consultative Committee for Pharmacology & Toxicology on 22 November 2001.Ulster Med J. 2003 Nov;72(2):73-9. Ulster Med J. 2003. PMID: 14696816 Free PMC article. No abstract available.
-
Set-shifting ability and schizophrenia: a marker of clinical illness or an intermediate phenotype?Biol Psychiatry. 2008 Nov 1;64(9):782-8. doi: 10.1016/j.biopsych.2008.05.009. Epub 2008 Jul 2. Biol Psychiatry. 2008. PMID: 18597738 Free PMC article.
-
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.Psychopharmacology (Berl). 2003 Sep;169(3-4):257-97. doi: 10.1007/s00213-002-1313-x. Epub 2003 Feb 25. Psychopharmacology (Berl). 2003. PMID: 12601500 Review.
-
Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2/D3 antagonism, D2/D3 partial agonism and placebo.Mol Psychiatry. 2025 Jul 19. doi: 10.1038/s41380-025-03116-8. Online ahead of print. Mol Psychiatry. 2025. PMID: 40684007
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources